Email
Print
Live Discussion
More Question and Answer sessions will be scheduled soon. Check back!
TMA's Live Discussion Series is not your typical chat program! Click here to learn how to participate.
JOIN LIVE CHAT NOW
Past Discussions
Tuesday, Apr 27, 11:00-12:00 PM EST
Myositis and Heart Disease
Dr. Robert Cooper is Consultant and Honorary Reader in Rheumatology at Hope Hospital, Salford and the University of Manchester, United Kingdom, and a member of TMA's Medical Advisory Board. Later this year, he will begin an investigation of the connection between heart disease and myositis. Click here to read the transcript.
Myositis and Heart Disease
Dr. Robert Cooper is Consultant and Honorary Reader in Rheumatology at Hope Hospital, Salford and the University of Manchester, United Kingdom, and a member of TMA's Medical Advisory Board. Later this year, he will begin an investigation of the connection between heart disease and myositis. Click here to read the transcript.
Monday, Jul 26, 3:00-4:00 PM EST
JM Treatment
Dr. Adam Huber is Pediatric Rheumatologist at the IWK Health Centre and an associate professor of Pediatrics at Dalhousie University in Halifax Nova Scotia. He did his pediatric rheumatology training at the Hospital for Sick Children, where he developed an interest in juvenile myositis while working with Dr. Brian Feldman. He is an active clinician, with a particular research interest in the assessment of disease activity and outcome in children with juvenile myositis. Click here to read the transcript.
JM Treatment
Dr. Adam Huber is Pediatric Rheumatologist at the IWK Health Centre and an associate professor of Pediatrics at Dalhousie University in Halifax Nova Scotia. He did his pediatric rheumatology training at the Hospital for Sick Children, where he developed an interest in juvenile myositis while working with Dr. Brian Feldman. He is an active clinician, with a particular research interest in the assessment of disease activity and outcome in children with juvenile myositis. Click here to read the transcript.
Wednesday, Nov 3, 3:00-4:00 PM EST
Understanding PM and IBM
Dr Anthony Amato is the vice-chairman of the Department of Neurology and the Director of the Neuromuscular Division and Clinical Neurophysiology Laboratory at Brigham and Women’s Hospital in Boston and a Professor of Neurology at Harvard Medical School. He is the chair-elect of the Neuromuscular Section of the American Academy of Neurology. He is the director of the Partners Neuromuscular Medicine fellowship program. His extensive research and published work reflects his long-time interest in DM, PM and IBM. Click here to read the transcript.
Understanding PM and IBM
Dr Anthony Amato is the vice-chairman of the Department of Neurology and the Director of the Neuromuscular Division and Clinical Neurophysiology Laboratory at Brigham and Women’s Hospital in Boston and a Professor of Neurology at Harvard Medical School. He is the chair-elect of the Neuromuscular Section of the American Academy of Neurology. He is the director of the Partners Neuromuscular Medicine fellowship program. His extensive research and published work reflects his long-time interest in DM, PM and IBM. Click here to read the transcript.
Wednesday, May 18, 4:00-5:00 PM EST
Myositis and intravenous immunogloblin
Dr. Tahseen Mozaffar will be featured in a live discussion about the use of IVIG in myositis treatment on Wednesday, May 18 at 4 pm ET. Dr Mozaffar is a neurologist, an associate professor of neurology at the University of California (Irvine) School of Medicine, and he directs the neuromuscular program at the UCI School of Medicine. He is also the director of the UCI-MDA ALS and Neuromuscular Center. He is a member of TMA’s medical advisory board. Click here to read the transcript.
Myositis and intravenous immunogloblin
Dr. Tahseen Mozaffar will be featured in a live discussion about the use of IVIG in myositis treatment on Wednesday, May 18 at 4 pm ET. Dr Mozaffar is a neurologist, an associate professor of neurology at the University of California (Irvine) School of Medicine, and he directs the neuromuscular program at the UCI School of Medicine. He is also the director of the UCI-MDA ALS and Neuromuscular Center. He is a member of TMA’s medical advisory board. Click here to read the transcript.
Thursday, Oct 6, 12:00-1:00 PM EST
Myositis and Lung Disease
Dr. Sonye Danoff of the Johns Hopkins Myositis Center will answer questions about myositis-associated lung problems Thursday, October 6, 2011 at 12 Noon EST.
Dr. Danoff is an Assistant Professor in the Division of Pulmonary and Critical Care Medicine and Co-Director of the Hopkins Interstitial Lung Disease Clinic. She is a specialist in diseases causing fibrosis or scarring in the lung, particularly those associated with autoimmune diseases including myositis. Her research focuses on basic and translational studies of lung fibrosis. She was awarded the 2007 American Thoracic Society/Coalition for Pulmonary Fibrosis Research Award to support her research studies. She has also been a recipient of grants from the National Institutes of Health, the Mid-Atlantic American Heart Association and the American Lung Association.
Click here to read the transcript.
Myositis and Lung Disease
Dr. Sonye Danoff of the Johns Hopkins Myositis Center will answer questions about myositis-associated lung problems Thursday, October 6, 2011 at 12 Noon EST.
Dr. Danoff is an Assistant Professor in the Division of Pulmonary and Critical Care Medicine and Co-Director of the Hopkins Interstitial Lung Disease Clinic. She is a specialist in diseases causing fibrosis or scarring in the lung, particularly those associated with autoimmune diseases including myositis. Her research focuses on basic and translational studies of lung fibrosis. She was awarded the 2007 American Thoracic Society/Coalition for Pulmonary Fibrosis Research Award to support her research studies. She has also been a recipient of grants from the National Institutes of Health, the Mid-Atlantic American Heart Association and the American Lung Association.
Click here to read the transcript.
Monday, Jan 30, 1:00-2:00 PM EST
Treatment and Outcomes in Juvenile Myositis
Dr. Brian Feldman, a pediatric rheumatologist, is Professor of Pediatrics, Medicine, Health Policy Management & Evaluation, at the University of Toronto and Division Head of Rheumatology at The Hospital for Sick Children in Toronto.
Dr. Feldman’s main focus is clinical research in the field of childhood rheumatic disease. Recognizing the challenges involved in the study of rare disease Dr. Feldman has worked to improve the tools available to assist in this research. He has worked at developing and refining outcome measurement tools for use in clinical trials and in outcome studies.
Dr. Feldman is a member of the TMA Medical Advisory Board, the Pediatric Rheumatology Collaborative Study Group, the Canadian Alliance of Pediatric Rheumatology Investigators, the International Myositis Assessment Criteria study group, and other collaborative organizations. He was one of the founding members of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was the head of the protocol evaluation subcommittee and chair of the Juvenile Dermatomyositis subcommittee.
Click here to read the transcript.
Treatment and Outcomes in Juvenile Myositis
Dr. Brian Feldman, a pediatric rheumatologist, is Professor of Pediatrics, Medicine, Health Policy Management & Evaluation, at the University of Toronto and Division Head of Rheumatology at The Hospital for Sick Children in Toronto.
Dr. Feldman’s main focus is clinical research in the field of childhood rheumatic disease. Recognizing the challenges involved in the study of rare disease Dr. Feldman has worked to improve the tools available to assist in this research. He has worked at developing and refining outcome measurement tools for use in clinical trials and in outcome studies.
Dr. Feldman is a member of the TMA Medical Advisory Board, the Pediatric Rheumatology Collaborative Study Group, the Canadian Alliance of Pediatric Rheumatology Investigators, the International Myositis Assessment Criteria study group, and other collaborative organizations. He was one of the founding members of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was the head of the protocol evaluation subcommittee and chair of the Juvenile Dermatomyositis subcommittee.
Click here to read the transcript.